Literature DB >> 19240583

Giant cell ependymoma of the thoracic spine: pathology case report.

Mohammed F Shamji1, Brien G Benoit, Arie Perry, Gerard H Jansen.   

Abstract

UNLABELLED: INTRODUCTION AND IMPORTANCE: Spinal ependymomas are slow-growing lesions that comprise the majority of primary spinal cord neoplasms. When surgery is indicated, the extent of tumor removal is most prognostic for long-term survival. Unusual histological subtypes can make intraoperative diagnosis spurious, possibly altering the surgical approach from gross total resection for ependymomas to debulking for high-grade astrocytomas. CLINICAL
PRESENTATION: We describe a 67-year-old woman with a thoracic spine intramedullary giant cell ependymoma. She presented with decreased lower extremity sensation leading to unsteadiness and an eventual fall. A physical examination revealed lower extremity hyperreflexia and ankle clonus, but no clear sensory level. Magnetic resonance imaging demonstrated an intramedullary T1 and T2 hypointense, homogenously enhancing lesion at T8 with extensive cephalad and caudal edema. INTERVENTION AND TECHNIQUE: A laminectomy at T8 to T9 afforded gross total resection of the lesion that had a clear cleavage plane with normal spinal cord. Intraoperative pathology suggested a high-grade glioblastoma, but final section showed sporadic giant cells with marked pleomorphism, uniform immunofluorescence staining with both glial fibrillary acidic protein and cluster of differentiation 99, and high MIB-1 index. Electron microscopy showed "zipper-like" junctions. There were no detected genomic abnormalities consistent with glioblastoma.
CONCLUSION: We present this first reported case of thoracic spine giant cell ependymoma alongside scant literature yielding 1 case in the cervical spine and 2 cases at the filum terminale. Those cases had benign courses, whereas ours demonstrates a high degree of proliferation, making the malignant potential difficult to assess.

Entities:  

Mesh:

Year:  2009        PMID: 19240583     DOI: 10.1227/01.NEU.0000338428.01654.A4

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  7 in total

Review 1.  Giant cell ependymoma-report of three cases and review of the literature.

Authors:  Jian Yi Li; Jose I Lopez; Suzanne Z Powell; Stephen W Coons; Gregory N Fuller
Journal:  Int J Clin Exp Pathol       Date:  2012-05-05

2.  'Serpent in the spine': a case of giant spinal ependymoma of cervicothoracic spine.

Authors:  Arlizan Arrifin; Chandrasekaran Kaliaperumal; Catherine Keohane; Michael O'Sullivan
Journal:  BMJ Case Rep       Date:  2012-06-27

3.  Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas.

Authors:  Michael C Oh; Michael E Ivan; Matthew Z Sun; Gurvinder Kaur; Michael Safaee; Joseph M Kim; Eli T Sayegh; Derick Aranda; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-12-09       Impact factor: 12.300

4.  Spinal ependymomas: benefits of extent of resection for different histological grades.

Authors:  Michael C Oh; Phiroz E Tarapore; Joseph M Kim; Matthew Z Sun; Michael Safaee; Gurvinder Kaur; Derick M Aranda; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2013-06-12       Impact factor: 1.961

5.  Cytologic features of giant cell ependymoma: a case report and review of the literature.

Authors:  Myoung Ju Koh; Sun Och Yoon; Hyae Min Jeon; Hyeon Joo Jeong; Soon Won Hong; Se Hoon Kim
Journal:  Korean J Pathol       Date:  2012-10-25

6.  Outcome predictors in the management of intramedullary classic ependymoma: An integrative survival analysis.

Authors:  Yinqing Wang; Ranze Cai; Rui Wang; Chunhua Wang; Chunmei Chen
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

7.  Factors associated with postoperative outcomes in patients with intramedullary Grade II ependymomas: A Systematic review and meta-analysis.

Authors:  Xiang-Yao Sun; Wei Wang; Tong-Tong Zhang; Chao Kong; Si-Yuan Sun; Ma-Chao Guo; Jun-Zhe Ding; Shi-Bao Lu
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.